Bayer's $7B Bet: A Bold Shift to Revive Its Eye Disease Pipeline

Bayer has agreed to acquire Perfuse Therapeutics, a biotech firm focused on eye diseases. The deal marks a shift in strategy after years of smaller, early-stage purchases. This move aims to strengthen the company’s ophthalmology division as key patents near expiry. The acquisition follows Bayer’s recent trend of buying early-stage innovations, including ASK Bio, Vividion, and Kandy Therapeutics. Together, these deals have cost nearly USD 7 billion. However, Perfuse represents a return to larger-scale, later-phase investments.

The centrepiece of the deal is PER-001, an endothelin receptor antagonist currently in Phase II trials. It targets glaucoma and diabetic retinopathy, conditions with significant unmet medical needs. Bayer believes the drug could become a disease-modifying therapy, offering a major advance over existing treatments. Bayer’s ophthalmology portfolio has relied heavily on Eylea, but its patent is set to expire. The company now faces pressure to find new growth drivers. Perfuse’s pipeline, with its more advanced clinical programmes, could help secure mid-term revenue and reduce dependency on older drugs.

The acquisition bolsters Bayer’s ophthalmology division at a critical time. PER-001’s potential as a disease-modifying treatment may address gaps in glaucoma and diabetic retinopathy care. If successful, the deal could offset losses from Eylea’s patent expiry while reinforcing the company’s long-term pipeline.